Aker BioMarine, a biotech company known for its krill harvesting, has recently received the first patent allowance for its PL+ DHA/EPA delivery technology platform. This new platform aims to increase the bioavailability of EPA and DHA by utilizing natural marine phospholipids (PLs) in formulations.
The PL+ formulation, introduced in late 2022, is designed to enhance absorption by combining krill phospholipids with EPA and DHA from processed fish oil. It allows for solubility in both fats and water, acting as an emulsifier and absorption booster, ultimately enhancing uptake of supplements.
The patent application protects the PL+ EPA/DHA technology by specifying certain features of lipid formulations for therapeutic use. This includes a certain percentage of phospholipids and DHA/EPA in ethyl ester form. The patent highlights Aker BioMarine’s commitment to innovation in utilizing the full potential of krill oil phospholipids, as stated by CEO of Human Health Ingredients, Simon Seward.
Seward emphasized that in a market where consumers seek personalized and combined products targeting specific health benefits, PL+ can help reduce dependence on fish oil formulas, increase bioavailability, enhance consumer experience, and foster new innovations in the industry. This patent represents a significant step forward for Aker BioMarine in advancing industry innovation.